UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.84-87

2017

Volltextzugriff (PDF)

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

Seminars in cancer biology, 2018-10, Vol.52 (Pt 2), p.259-268

2018

Volltextzugriff (PDF)

MS04.02 Neo-Adjuvant PD-(L)1 Checkpoint Inhibitors

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S155-S156

Raez, L.

2019

Volltextzugriff (PDF)

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial

ESMO open, 2024-05, Vol.9 (5), p.103444, Article 103444

2024

Volltextzugriff (PDF)

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013-09, Vol.81 (3), p.416-421

2013

Volltextzugriff (PDF)

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

Annals of oncology, 2009-05, Vol.20 (5), p.921-927

2009

Volltextzugriff (PDF)

3PD Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S58-S58

2016

Volltextzugriff (PDF)

MA19.05 Improving Lung Cancer Outcomes and Quality in the US Community Setting with the Creation of Lung Cancer Centers of Excellence Program

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S327-S328

2019

Volltextzugriff (PDF)

P44.01 Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1083-S1083

2021

Volltextzugriff (PDF)

MA06.07 Inferior Outcomes in Minority Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC) After Durvalumab Consolidation Therapy

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S904-S905

2021

Volltextzugriff (PDF)

P01.12 Brain Necrosis in Patients With Metastatic Lung and Breast Cancer Successfully Treated With Bevacizumab

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S241-S241

2021

Volltextzugriff (PDF)

OA 11.07 Enhancing Lung Cancer (LC) Care in the Community Setting Through a Patient Advocacy 'Centers of Excellence' (COE) Program

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1775-S1775

2017

Volltextzugriff (PDF)

P2.07-052 Detection of KRAS Mutation in Blood Predicts Favorable Response to Immunotherapy in NSCLC

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2149-S2149

2017

Volltextzugriff (PDF)

EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S452

2022

Volltextzugriff (PDF)

EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S635-S635

2024

Volltextzugriff (PDF)

Has Survival for Patients with Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy Improved Over Time?

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S426-S426

2010

Volltextzugriff (PDF)

P14.04 cfRNA from Liquid Biopsies Is More Abundant Than cfDNA, Informs Treatment Outcome and Is Concordant with Tissue

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S330-S330

2021

Volltextzugriff (PDF)

P33.14 STK11/LKB1, KRAS Mutations and Immune-Related Adverse Events as Predictors of Response to Immunotherapy in Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S411-S411

2021

Volltextzugriff (PDF)

Neo-Adjuvant PD-(L)1 Checkpoint Inhibitors: MS04.02

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S155-S156

Raez, L

2019

Volltextzugriff (PDF)

EP12.01-61 Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S666

2023

Volltextzugriff (PDF)

P2.10-13 Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S357-S358

2023

Volltextzugriff (PDF)

EP12.01-65 Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S667-S668

2023

Volltextzugriff (PDF)

EP12.03-04 Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S681

2023

Volltextzugriff (PDF)

P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S275-S276

2024

Volltextzugriff (PDF)

PD1.06 Improving Survival of Oligometastatic NSCLC with Stereotactic Body Radiation Therapy

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1168-S1169

2019

Volltextzugriff (PDF)

1 – 25 von 242

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(219)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(96)
Life Sciences & Biomedicine
(60)
Humans
(50)
Technology
(33)
Female
(31)
Male
(29)
Oncology
(26)
Computer Science
(24)
Aged
(22)
Middle Aged
(20)
Adult
(18)
Biological And Medical Sciences
(14)
Computer Science, Artificial Intelligence
(13)
Engineering
(12)
Lung Neoplasms - Drug Therapy
(12)
Medical Sciences
(12)
Computer Science, Information Systems
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Neoplasms - Pathology
(10)
Computer Science, Theory & Methods
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

MS04.02 Neo-Adjuvant PD-(L)1 Checkpoint Inhibitors

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

3PD Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile

MA19.05 Improving Lung Cancer Outcomes and Quality in the US Community Setting with the Creation of Lung Cancer Centers of Excellence Program

P44.01 Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

MA06.07 Inferior Outcomes in Minority Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC) After Durvalumab Consolidation Therapy

P01.12 Brain Necrosis in Patients With Metastatic Lung and Breast Cancer Successfully Treated With Bevacizumab

OA 11.07 Enhancing Lung Cancer (LC) Care in the Community Setting Through a Patient Advocacy 'Centers of Excellence' (COE) Program

P2.07-052 Detection of KRAS Mutation in Blood Predicts Favorable Response to Immunotherapy in NSCLC

EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer

EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America

Has Survival for Patients with Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy Improved Over Time?

P14.04 cfRNA from Liquid Biopsies Is More Abundant Than cfDNA, Informs Treatment Outcome and Is Concordant with Tissue

P33.14 STK11/LKB1, KRAS Mutations and Immune-Related Adverse Events as Predictors of Response to Immunotherapy in Lung Cancer

Neo-Adjuvant PD-(L)1 Checkpoint Inhibitors: MS04.02

EP12.01-61 Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

P2.10-13 Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice

EP12.01-65 Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC

EP12.03-04 Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib

P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

PD1.06 Improving Survival of Oligometastatic NSCLC with Stereotactic Body Radiation Therapy

Suchergebnisse filtern